Share this
autism and cannabinoids: catching up with exciting pediatric research
by Neoteryx Microsampling on Oct 4, 2018 3:39:00 AM
VAMS® microsampling opens new possibilities in the realm of drug testing, such as our breakthrough work with Alcala Labs. These range from new options in fighting the opioid crisis to exciting new realms of research in pediatrics that may improve conditions for children classified on the autism spectrum.
Children's Hospital of Philadelphia is right now in the process of making significant strides in pediatrics study to determine the effects of medical marijuana on children with autism. The study is to be conducted in conjunction with an Australian based biopharmaceutical company called Zelda Therapeutics. It involves working with families with children suffering from autism and are under medication of medical cannabis from state-approved dispensaries.
The participating families are expected to be interviewed for one hour over the phone to give information concerning the medical background of their child, complete voluntary study materials, as well as provide the information on cannabis use on their children.
About Autism Spectrum Disorder
Autism spectrum disorder affects a large number of children across the world. There is no cure for this condition. However, there are few treatments administered to manage the condition. Cannabis treatments show a potential success in the treatment of autism in pediatrics.
There have been many success stories in the treatment of autism in children, which would not be there if parents solely depended on the traditionally prescribed medications. This has only been enabled by the research conducted on cannabinoids and introduction of the medical marijuana.
There have been reports from parents whose children have autism spectrum disorder showing that use of cannabis improves the symptoms in their children. Clinical trials, therefore, are much needed to prove the safe and effective compounds to treat this disorder. According to studies, medicinal cannabidiol (CBD) is potentially useful in treating conditions such as obsessive-compulsiveness, anxiety, post-traumatic stress, and others. A CBD-based drug has recently been recommended by an advisory panel of Food and Drug Administration to treat epilepsy in childhood.
Some states have approved the use of medical marijuana where parents can access them and use them for problems such as aggressiveness, sleeping problems, and anxiety in their children. The clinical research by different institutions promises that marijuana might in the future be one of the most effective drugs for autism in pediatrics.
In the process of development of a new drug, it is important to obtain precise outcomes on the effects of the drug in an individual. Drug testing methods such as drug metabolism and pharmacokinetic require blood samples and VAMS® microsampling is one of the most exciting innovations in collecting blood samples for research.
Share this
- Microsampling (206)
- Research, Remote Research (119)
- Venipuncture Alternative (106)
- Clinical Trials, Clinical Research (83)
- Mitra® Device (74)
- Therapeutic Drug Monitoring, TDM (51)
- Dried Blood Spot, DBS (38)
- Biomonitoring, Health, Wellness (31)
- Infectious Disease, Vaccines, COVID-19 (24)
- Blood Microsampling, Serology (22)
- Decentralized Clinical Trial (DCT) (22)
- Omics, Multi-Omics (20)
- Specimen Collection (17)
- Toxicology, Doping, Drug/Alcohol Monitoring, PEth (17)
- hemaPEN® Device (13)
- Preclinical Research, Animal Studies (12)
- Skin Microsampling, Microbiopsy (12)
- Pharmaceuticals, Drug Development (9)
- Harpera Device (5)
- Industry News, Microsampling News (5)
- Antibodies, MAbs (3)
- Company Press Release, Product Press Release (3)
- Environmental Toxins, Exposures (1)
- December 2024 (2)
- November 2024 (1)
- October 2024 (3)
- September 2024 (1)
- June 2024 (1)
- May 2024 (1)
- April 2024 (4)
- March 2024 (1)
- February 2024 (2)
- January 2024 (4)
- December 2023 (3)
- November 2023 (3)
- October 2023 (3)
- September 2023 (3)
- July 2023 (3)
- June 2023 (2)
- April 2023 (2)
- March 2023 (2)
- February 2023 (2)
- January 2023 (3)
- December 2022 (2)
- November 2022 (3)
- October 2022 (4)
- September 2022 (3)
- August 2022 (5)
- July 2022 (2)
- June 2022 (2)
- May 2022 (4)
- April 2022 (3)
- March 2022 (3)
- February 2022 (4)
- January 2022 (5)
- December 2021 (3)
- November 2021 (5)
- October 2021 (3)
- September 2021 (3)
- August 2021 (4)
- July 2021 (4)
- June 2021 (4)
- May 2021 (4)
- April 2021 (3)
- March 2021 (5)
- February 2021 (4)
- January 2021 (4)
- December 2020 (3)
- November 2020 (5)
- October 2020 (4)
- September 2020 (3)
- August 2020 (3)
- July 2020 (6)
- June 2020 (4)
- May 2020 (4)
- April 2020 (3)
- March 2020 (6)
- February 2020 (3)
- January 2020 (4)
- December 2019 (5)
- November 2019 (4)
- October 2019 (2)
- September 2019 (4)
- August 2019 (4)
- July 2019 (3)
- June 2019 (7)
- May 2019 (6)
- April 2019 (5)
- March 2019 (6)
- February 2019 (5)
- January 2019 (8)
- December 2018 (3)
- November 2018 (4)
- October 2018 (7)
- September 2018 (6)
- August 2018 (5)
- July 2018 (8)
- June 2018 (6)
- May 2018 (5)
- April 2018 (6)
- March 2018 (4)
- February 2018 (6)
- January 2018 (4)
- December 2017 (2)
- November 2017 (3)
- October 2017 (2)
- September 2017 (4)
- August 2017 (2)
- July 2017 (4)
- June 2017 (5)
- May 2017 (6)
- April 2017 (6)
- March 2017 (5)
- February 2017 (4)
- January 2017 (1)
- July 2016 (3)
- May 2016 (1)
- April 2016 (2)
No Comments Yet
Let us know what you think